Current Opinion (Lippincott Williams & Wilkins)

Experts Call for Protocols to Speed up Referrals for Pulmonary Hypertension to Specialized Centers

Retrieved on: 
星期一, 七月 3, 2023
Science, Cardiology, Other Science, Biotechnology, Research, Pharmaceutical, Health, Other Health, E pluribus unum, Business development, Prevalence, Classification, Quality of life, Pulmonary Circulation, Medical school, Prognosis, Pulmonology, Multimedia, Human, Current Opinion (Lippincott Williams & Wilkins), Pulmonary hypertension, McMurray, The Lancet, International Meeting for Autism Research, Medical University of Graz, Patient, PH, Diagnosis, Mortality, ESC, Orthostatic hypertension, Disease, Pharmaceutical industry, Medical device, Silviculture

Recent data shows that, despite advances in recent years, the time from onset of symptoms to diagnosis of pulmonary arterial hypertension, for example, is more than 2 years1.

Key Points: 
  • Recent data shows that, despite advances in recent years, the time from onset of symptoms to diagnosis of pulmonary arterial hypertension, for example, is more than 2 years1.
  • These advances represent a promising opportunity to improve outcomes for people with pulmonary arterial hypertension.
  • Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension.
  • The trouble with group 3 pulmonary hypertension in interstitial lung disease: dilemmas in diagnosis and the conundrum of treatment.

Cybin Selects Generalized Anxiety Disorder as Target Indication for Deuterated DMT Molecule CYB004

Retrieved on: 
星期四, 一月 12, 2023
Biotechnology, Neurology, Mental Health, Health, Clinical Trials, Anxiety disorder, Inc., Scientific Reports, Disease, Comorbidity, SSRI, Injury, Psychedelic drug, Depression, Anxiety, McIntyre, DMT, Quality of life, Safety, NEO, Lancet, NYSE, Global Burden of Disease Study, MDD, Current Opinion (Lippincott Williams & Wilkins), GAD, Generalized anxiety disorder, Patient, IV, Therapy, Prevalence, Recurrence, Human, Pharmaceutical industry, Birth control

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) (Cybin or the Company), a biotechnology company focused on progressing Psychedelics to Therapeutics® today announced that it has selected Generalized Anxiety Disorder (“GAD”) with or without major depressive disorder (“MDD”) as the target indication for its proprietary deuterated N, N-dimethyltryptamine (“DMT”) molecule, CYB004.

Key Points: 
  • Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) (Cybin or the Company), a biotechnology company focused on progressing Psychedelics to Therapeutics® today announced that it has selected Generalized Anxiety Disorder (“GAD”) with or without major depressive disorder (“MDD”) as the target indication for its proprietary deuterated N, N-dimethyltryptamine (“DMT”) molecule, CYB004.
  • "Based on preclinical data, CYB004 has shown promise in treating anxiety disorders.
  • Over 40 million adults in the U.S. (19.1% of the total U.S. population) have an anxiety disorder.1
    Additional Facts about Anxiety and Generalized Anxiety Disorder:
    Among psychiatric disorders, GAD and MDD are the leading contributors to global disability.
  • Comorbid generalized anxiety disorder and its association with quality of life in patients with major depressive disorder.

The Columbus Organization Advances an Innovative Care Coordination Model for Complex Care Lives

Retrieved on: 
星期二, 六月 28, 2022
View, LinkedIn, Anxiety, Medicaid, Journal of Intellectual & Developmental Disability, SharePoint, Polypharmacy, Senior, Analytics, Medicare Advantage, Population, Quality assurance, Cancer, Multimedia, Technology Innovation Institute, Depression, Joint Support Coordination Cell, Prevalence, Obesity, Current Opinion (Lippincott Williams & Wilkins), BLUE, HIV, Risk, Communication, University, Lists of diseases, Organization, Doctor of Philosophy, Museum of Black Arkansans and Performing Arts Center, Health, Health insurance marketplace, LBA, Disability in Canada, IDD, Medicare, CareSource, Twitter, Asthma, Thought, Diabetes, Health insurance, Psychiatry

Melissa Richards, PhD, LBA, BCBA-D, Senior Vice President of Clinical Operations for The Columbus Organization, commented, "We see complex care as a real-time, person-centered, data-driven approach that requires interdisciplinary care teams and cross-sector partnerships to achieve optimal outcomes.

Key Points: 
  • Melissa Richards, PhD, LBA, BCBA-D, Senior Vice President of Clinical Operations for The Columbus Organization, commented, "We see complex care as a real-time, person-centered, data-driven approach that requires interdisciplinary care teams and cross-sector partnerships to achieve optimal outcomes.
  • The Columbus Organization recently presented greater detail on this novel approach to coordinating care for complex populations at the recent Open Minds Strategies and Innovation Institute conference held June 14-16, 2022.
  • For 38+ years, The Columbus Organization has been a national leader and pioneer in care coordination specifically for individuals living with intellectual/developmental disabilities, behavioral concerns, or complex care needs.
  • For more, visit www.ColumbusOrg.com , follow @TheColumbusOrg on Twitter , like The Columbus Organization on Facebook , or follow The Columbus Organization on LinkedIn .